Bear Stearns Health Innoventures L.P
VC Fund
New York, United States
Bear Stearns Health Innoventures L.P is a VC fund in New York focused on Biotechnology and Health Care. Bear Stearns Health Innoventures Management, L.L.C. is a venture capital firm specializing in early and mid stage investments.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Bear Stearns Health Innoventures L.P invests in
Stages Bear Stearns Health Innoventures L.P invests in
Countries Bear Stearns Health Innoventures L.P invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Elizabeth Adkins Czerepak
|
|||
Investment Focus
Industry
- Biotechnology 7 (88%)
- Health Care 5 (63%)
- Medical 4 (50%)
- Therapeutics 3 (38%)
- Biopharma 2 (25%)
Stage
- Series C 5 (63%)
- Series D 2 (25%)
- Series B 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Elizabeth Adkins Czerepak
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Affymax
|
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidneydisease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA). | $60M / Series D / Jul 18, 2005 | |
Tolerx
|
Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385,pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts. | $31M / Series D / Mar 29, 2005 | |
PharmAthene
|
PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, arecombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland. | $50M / Series B / Oct 12, 2004 | |
AGY Therapeutics
|
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform forfunctional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY. | $9M / Series C / Aug 07, 2004 | |
|
Affymax
|
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematideâ„¢), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidneydisease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA). | $20M / Series C / Apr 14, 2004 | |
Corus Pharma
|
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of thecompany are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma.Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006. | $65M / Series C / Apr 13, 2004 | |
Raven Biotechnologies
|
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 andis based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc. | $40M / Series C / Jan 03, 2003 | |
Entelos
|
Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success.For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutionsinclude mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise. | $25M / Series C / Sep 06, 2001 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bear Stearns Health Innoventures L.P invest in?
Bear Stearns Health Innoventures L.P invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bear Stearns Health Innoventures L.P?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bear Stearns Health Innoventures L.P?
The team at Bear Stearns Health Innoventures L.P includes Elizabeth Adkins Czerepak (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
